Close Menu

NEW YORK – Finnish molecular diagnostics firm Mobidiag said on Tuesday that its Novodiag COVID-19 and Amplidiag COVID-19 PCR tests have received CE-IVD marking.

The Novodiag COVID-19 test uses nasopharyngeal swabs to detect the SARS-CoV-2 orf1ab and N genes and runs on Mobidiag's Novodiag rapid fully automated system, providing results in an hour. The company noted that its platform is user friendly and closed, which means it can protect users from contamination and can be used in decentralized areas.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.